Axonics Stock Debt To Equity

0I3 Stock  EUR 63.50  0.00  0.00%   
Axonics fundamentals help investors to digest information that contributes to Axonics' financial success or failures. It also enables traders to predict the movement of Axonics Stock. The fundamental analysis module provides a way to measure Axonics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Axonics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Axonics Company Debt To Equity Analysis

Axonics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Axonics Debt To Equity

    
  0.02 %  
Most of Axonics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axonics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, Axonics has a Debt To Equity of 0.019%. This is 99.96% lower than that of the Healthcare sector and 99.95% lower than that of the Medical Devices industry. The debt to equity for all Germany stocks is 99.96% higher than that of the company.

Axonics Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axonics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axonics could also be used in its relative valuation, which is a method of valuing Axonics by comparing valuation metrics of similar companies.
Axonics is currently under evaluation in debt to equity category among its peers.

Axonics Fundamentals

About Axonics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Axonics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axonics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axonics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Axonics Stock

Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.